# Duloxetine for PHN

> **NCT04313335** · NA · COMPLETED · sponsor: **Beijing Tiantan Hospital** · enrollment: 750 (actual)

## Conditions studied

- Postherpetic Neuralgia

## Interventions

- **DRUG:** Duloxetine

## Key facts

- **NCT ID:** NCT04313335
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-01
- **Primary completion:** 2023-05-16
- **Final completion:** 2023-05-16
- **Target enrollment:** 750 (ACTUAL)
- **Last updated:** 2024-01-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04313335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04313335, "Duloxetine for PHN". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04313335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*